LDZU Stock Overview
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for LDZU from our risk checks.
Aspen Pharmacare Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R10.20 |
| 52 Week High | R10.60 |
| 52 Week Low | R7.50 |
| Beta | 0.75 |
| 1 Month Change | 2.51% |
| 3 Month Change | 13.33% |
| 1 Year Change | 17.24% |
| 3 Year Change | 10.87% |
| 5 Year Change | n/a |
| Change since IPO | 33.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDZU | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.8% | -3.1% | -2.0% |
| 1Y | 17.2% | -31.9% | -0.3% |
Return vs Industry: LDZU exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: LDZU exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| LDZU volatility | |
|---|---|
| LDZU Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LDZU has not had significant price volatility in the past 3 months.
Volatility Over Time: LDZU's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1850 | 8,887 | Stephen Saad | www.aspenpharma.com |
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand.
Aspen Pharmacare Holdings Limited Fundamentals Summary
| LDZU fundamental statistics | |
|---|---|
| Market cap | €4.70b |
| Earnings (TTM) | €237.44m |
| Revenue (TTM) | €2.08b |
19.5x
P/E Ratio2.2x
P/S RatioIs LDZU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDZU income statement (TTM) | |
|---|---|
| Revenue | R42.70b |
| Cost of Revenue | R23.49b |
| Gross Profit | R19.22b |
| Other Expenses | R14.35b |
| Earnings | R4.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 03, 2024
| Earnings per share (EPS) | 10.94 |
| Gross Margin | 45.00% |
| Net Profit Margin | 11.40% |
| Debt/Equity Ratio | 42.2% |
How did LDZU perform over the long term?
See historical performance and comparison